Carlos Bravo‐Pérez

696 total citations
39 papers, 321 citations indexed

About

Carlos Bravo‐Pérez is a scholar working on Hematology, Genetics and Molecular Biology. According to data from OpenAlex, Carlos Bravo‐Pérez has authored 39 papers receiving a total of 321 indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Hematology, 13 papers in Genetics and 12 papers in Molecular Biology. Recurrent topics in Carlos Bravo‐Pérez's work include Blood Coagulation and Thrombosis Mechanisms (12 papers), Acute Myeloid Leukemia Research (10 papers) and Immunodeficiency and Autoimmune Disorders (5 papers). Carlos Bravo‐Pérez is often cited by papers focused on Blood Coagulation and Thrombosis Mechanisms (12 papers), Acute Myeloid Leukemia Research (10 papers) and Immunodeficiency and Autoimmune Disorders (5 papers). Carlos Bravo‐Pérez collaborates with scholars based in Spain, United States and Italy. Carlos Bravo‐Pérez's co-authors include Javier Corral, Vicente Vicente, María Eugenia de la Morena‐Barrio, Belén de la Morena‐Barrio, Antonia Miñano, Valeria Visconte, José I. Quetglas, María Buñuales, Rubén Hernández-Alcoceba and Joanna Poutou and has published in prestigious journals such as Blood, PLoS ONE and Scientific Reports.

In The Last Decade

Carlos Bravo‐Pérez

37 papers receiving 320 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Carlos Bravo‐Pérez Spain 10 145 103 84 74 67 39 321
Kazunori Murai Japan 12 152 1.0× 93 0.9× 69 0.8× 19 0.3× 8 0.1× 48 330
M. von Depka Prondzinski Germany 7 306 2.1× 52 0.5× 20 0.2× 27 0.4× 22 0.3× 23 418
Lip Kun Tan Singapore 11 93 0.6× 49 0.5× 131 1.6× 38 0.5× 9 0.1× 36 255
Ann Van de Velde Belgium 10 153 1.1× 124 1.2× 79 0.9× 58 0.8× 6 0.1× 29 373
Liza D. Robles United States 5 94 0.6× 145 1.4× 56 0.7× 6 0.1× 106 1.6× 6 349
Luc VanderElst Belgium 9 61 0.4× 47 0.5× 39 0.5× 38 0.5× 18 0.3× 11 341
Chiara Frairia Italy 10 147 1.0× 86 0.8× 100 1.2× 11 0.1× 16 0.2× 24 296
Jana Babatz Germany 9 42 0.3× 58 0.6× 89 1.1× 24 0.3× 19 0.3× 16 300
DW Hommes Netherlands 7 82 0.6× 26 0.3× 24 0.3× 237 3.2× 25 0.4× 13 371
Edward Abadir Australia 8 48 0.3× 51 0.5× 53 0.6× 18 0.2× 12 0.2× 19 358

Countries citing papers authored by Carlos Bravo‐Pérez

Since Specialization
Citations

This map shows the geographic impact of Carlos Bravo‐Pérez's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Carlos Bravo‐Pérez with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Carlos Bravo‐Pérez more than expected).

Fields of papers citing papers by Carlos Bravo‐Pérez

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Carlos Bravo‐Pérez. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Carlos Bravo‐Pérez. The network helps show where Carlos Bravo‐Pérez may publish in the future.

Co-authorship network of co-authors of Carlos Bravo‐Pérez

This figure shows the co-authorship network connecting the top 25 collaborators of Carlos Bravo‐Pérez. A scholar is included among the top collaborators of Carlos Bravo‐Pérez based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Carlos Bravo‐Pérez. Carlos Bravo‐Pérez is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Gurnari, Carmelo, Carlos Bravo‐Pérez, Arda Durmaz, et al.. (2025). Non canonical c-CBL mutations define a specific phenotype of myeloid neoplasia. Leukemia. 39(3). 748–751. 3 indexed citations
2.
Bravo‐Pérez, Carlos, José Padilla, María Eugenia de la Morena‐Barrio, et al.. (2024). The whole is greater than the sum of its parts: Long‐read sequencing for solving clinical problems in haematology. Journal of Cellular and Molecular Medicine. 28(3). e17961–e17961. 2 indexed citations
3.
Garrido, Pedro, María Eugenia de la Morena‐Barrio, Carlos Bravo‐Pérez, et al.. (2024). Analysis of AlphaFold and molecular dynamics structure predictions of mutations in serpins. PLoS ONE. 19(7). e0304451–e0304451. 9 indexed citations
4.
Bravo‐Pérez, Carlos, Zoe Brady, Arda Durmaz, et al.. (2024). Budd-Chiari Syndrome: Pathogenetic Factors and Completeness of Screening for Paroxysmal Nocturnal Hemoglobinuria. Blood. 144(Supplement 1). 1254–1254.
5.
Kubota, Yasuo, Carlos Bravo‐Pérez, Carmelo Gurnari, et al.. (2024). Genomic Landscape of Germline RUNX1 variants in Adult Myeloid Neoplasia According to Functional Impact. Blood. 144(Supplement 1). 1328–1328. 1 indexed citations
6.
Bravo‐Pérez, Carlos & Carmelo Gurnari. (2024). A tower of babel of acronyms? The shadowlands of MGUS/MBL/CHIP/TCUS. Seminars in Hematology. 61(1). 43–50. 2 indexed citations
7.
Bravo‐Pérez, Carlos, et al.. (2024). Thrombosis in Myeloid Malignancies: From CHIP to AML. Cardiovascular & Haematological Disorders - Drug Targets. 24(1). 2–12. 3 indexed citations
8.
Bravo‐Pérez, Carlos, et al.. (2024). KMT2A Rearrangements in Leukemias: Molecular Aspects and Therapeutic Perspectives. International Journal of Molecular Sciences. 25(16). 9023–9023. 9 indexed citations
9.
Bravo‐Pérez, Carlos, et al.. (2023). Immunotherapy in Acute Myeloid Leukemia: A Literature Review of Emerging Strategies. Bioengineering. 10(10). 1228–1228. 11 indexed citations
10.
Padilla, José, María Eugenia de la Morena‐Barrio, Belén de la Morena‐Barrio, et al.. (2023). Usefulness and Limitations of Multiple Ligation-Dependent Probe Amplification in Antithrombin Deficiency. International Journal of Molecular Sciences. 24(5). 5023–5023. 3 indexed citations
11.
Morena‐Barrio, Belén de la, José Padilla, Carlos Bravo‐Pérez, et al.. (2023). Impact of genetic structural variants in factor XI deficiency: identification, accurate characterization, and inferred mechanism by long-read sequencing. Journal of Thrombosis and Haemostasis. 21(7). 1779–1788. 1 indexed citations
12.
Natorska, Joanna, Javier Corral, María Eugenia de la Morena‐Barrio, et al.. (2023). Antithrombin Deficiency Is Associated with Prothrombotic Plasma Fibrin Clot Phenotype. Thrombosis and Haemostasis. 123(9). 880–891. 8 indexed citations
13.
Durmaz, Arda, Carlos Bravo‐Pérez, Yasuo Kubota, et al.. (2023). Association Vs Causation: Epidemiologic Clues As to the Autoimmune Pathogenesis of MDS. Blood. 142(Supplement 1). 4066–4066. 1 indexed citations
14.
Gurnari, Carmelo, Carlos Bravo‐Pérez, Arda Durmaz, et al.. (2023). Molecular Landscape of c-CBL Mutation in Adults' Myeloid Malignancies. Blood. 142(Supplement 1). 4336–4336. 1 indexed citations
15.
Morena‐Barrio, María Eugenia de la, Pierre Suchon, E. Jacobsen, et al.. (2022). Two SERPINC1 variants affecting N-glycosylation of Asn224 cause severe thrombophilia not detected by functional assays. Blood. 140(2). 140–151. 17 indexed citations
16.
Bravo‐Pérez, Carlos, Joseph E. Chambers, José A. Martínez‐Menárguez, et al.. (2022). Full-length antithrombin frameshift variant with aberrant C-terminus causes endoplasmic reticulum retention with a dominant-negative effect. JCI Insight. 7(19). 7 indexed citations
17.
Morena‐Barrio, María Eugenia de la, Carlos Bravo‐Pérez, Antonia Miñano, et al.. (2021). Prognostic value of thrombin generation parameters in hospitalized COVID-19 patients. Scientific Reports. 11(1). 7792–7792. 30 indexed citations
18.
Bravo‐Pérez, Carlos, Antonia Miñano, José Padilla, et al.. (2021). Anticoagulant therapy in patients with congenital FXI deficiency. Blood Advances. 5(20). 4083–4086. 3 indexed citations
19.
Nistal‐Villán, Estanislao, María Buñuales, Joanna Poutou, et al.. (2015). Enhanced therapeutic effect using sequential administration of antigenically distinct oncolytic viruses expressing oncostatin M in a Syrian hamster orthotopic pancreatic cancer model. Molecular Cancer. 14(1). 210–210. 15 indexed citations
20.
Poutou, Joanna, María Buñuales, Manuela González-Aparicio, et al.. (2015). Safety and antitumor effect of oncolytic and helper-dependent adenoviruses expressing interleukin-12 variants in a hamster pancreatic cancer model. Gene Therapy. 22(9). 696–706. 36 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Kazunori Murai Breakdown of academic impact, for papers by M. von Depka Prondzinski Breakdown of academic impact, for papers by Lip Kun Tan Breakdown of academic impact, for papers by Ann Van de Velde Breakdown of academic impact, for papers by Liza D. Robles Breakdown of academic impact, for papers by Luc VanderElst Breakdown of academic impact, for papers by Chiara Frairia Breakdown of academic impact, for papers by Jana Babatz Breakdown of academic impact, for papers by DW Hommes Breakdown of academic impact, for papers by Edward Abadir
Rankless by CCL
2026